key: cord-0844485-rl9seybu
authors: Breva, Silvia Montolio; Clavero, Carmen Molina; Bertomeu, Frederic Gómez; Picó-Plana, Ester; Orús, Núria Serrat; Sánchez, Inmaculada Palau; Prad, Maria Teresa Mestre; Mateu, Maria Teresa Sans
title: Evaluation of five immunoassays and one lateral flow immunochromatography for anti-SARS-CoV-2 antibodies detection
date: 2021-01-20
journal: Enferm Infecc Microbiol Clin
DOI: 10.1016/j.eimc.2020.12.002
sha: 0972a077ab7d481852f629aa8e8f42ea2577c402
doc_id: 844485
cord_uid: rl9seybu

Introduction: In order to deal with the current pandemic caused by the novel SARS-CoV-2 coronavirus several serological immunoassays have been recently developed with the objective of being used as a complementary diagnostic tool and to support the RT-PCR technique currently considered the “gold-standard” method. However, these new assays need to be evaluated and validated. The purpose of this study was to assess the performance of five immunoassays (two ELISA and three CLIA assays) and one rapid immunochromatographic test for the detection of anti-SARS-CoV-2 antibodies. Methods: Five semiquantitative immunoassays (MENARINI®, PALEX®, VIRCLIA®, ROCHE® and SIEMENS®) and one lateral flow rapid test (WONDFO®) were performed. A total of 124 samples were studied. Case serum samples (n=78) were obtained from COVID-19 patients confirmed by real-time RT-PCR/epidemiological-clinical-radiological criteria, and control non-SARS-CoV-2 samples (n=46) belonged to healthy healthcare workers involved in a seroprevalence study. Results: Overall, the tests showed sensitivities around 70-90% and specificities greater than 95%, including the immunochromatographic test. In addition, we observed very good agreements among them, being better for the detection of IgG than for IgM antibodies (Cohen’s kappa index of 0.95 for VIRCLIA® IgG with ROCHE®), as well as good diagnostic power of the tests as determined by the ROC curves. Conclusions: This study demonstrates the proper performance of the different immunoassays in order to be applied in the clinical practice as support in the diagnostic approach and in the development of vaccines and seroepidemiological studies of COVID-19. Introducción: Para hacer frente a la pandemia actual causada por el nuevo coronavirus SARS-CoV-2 se han desarrollado recientemente varios inmunoensayos serológicos con el objetivo de ser utilizados como herramienta diagnóstica complementaria y apoyar la técnica de RT-PCR actualmente considerada como el "estándar de oro". Sin embargo, estos nuevos ensayos deben evaluarse y validarse. El objetivo de este estudio fue evaluar cinco inmunoensayos (dos ELISA y tres ensayos CLIA) y una prueba inmunocromatográfica rápida para la detección de anticuerpos anti-SARS-CoV-2. Métodos: Se utilizaron cinco inmunoensayos semicuantitativos (MENARINI®, PALEX®, VIRCLIA®, ROCHE® y SIEMENS®) y un test de inmunocromatografía rápida (WONDFO®). Se estudiaron un total de 124 muestras. Las muestras de suero (n = 78) se obtuvieron de pacientes COVID-19 confirmados por RT-PCR en tiempo real / criterios epidemiológicos-clínico-radiológicos. Las muestras control negativas (n = 46) pertenecieron a personal sanitario involucrado en un estudio de seroprevalencia. Resultados: En general, las pruebas mostraron sensibilidades en torno al 70-90% y especificidades superiores al 95%, incluso la prueba inmunocromatográfica. Además, observamos muy buenas concordancias entre ellas, presentando mayores sensibilidades para la detección de anticuerpos IgG que para IgM (índice kappa de Cohen de 0,95 para VIRCLIA® IgG con ROCHE®), así como un buen poder diagnóstico de las técnicas determinado por las curvas ROC. Conclusiones: Este estudio demuestra el buen rendimiento de los diferentes inmunoensayos para ser empleados en la práctica clínica como apoyo en el proceso de diagnóstico, en el desarrollo de vacunas y estudios seroepidemiológicos de COVID-19.

J o u r n a l P r e -p r o o f 5 results. 7-12 Thus, the objective of this study was to evaluate a total of six CE-marked 92 immunoassays, including two enzyme-linked immunosorbent assays (ELISAs), three 93 chemiluminescence immunoassays (CLIAs) and one lateral flow rapid test, for the 94 detection of SARS-CoV-2 IgM, IgG and total antibodies in patients with COVID-19. 

Sensitivities and specificities of the assays 161 The sensitivities and specificities as well as the rest of predictive parameters are 162 summarized in Table 1 conclusion that S1 is more specific than S as an antigen for SARS-CoV-2 serological 244 diagnosis, as well as that RBD and N ELISAs were more sensitive than S1 ELISA in 245 detecting antibodies in mildly infected patients. Besides, they found differences 246 between immunoglobulins, being IgG the most specific. In conclusion, this study shows the adequate performance as well as the high level of 

A familial cluster of 334 pneumonia associated with the 2019 novel coronavirus indicating person-to-person 335 transmission: a study of a family cluster

World Health Organization

In vitro diagnostic assays for COVID-19: recent advances and emerging 348 trends

Developing antibody tests for SARS-CoV-2

Serological immunochromatographic 352 approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Evaluation of two automated and three rapid lateral flow immunoassays for the 356 detection of anti-SARS-CoV-2 antibodies

Dynamic 359 profile for the detection of anti-SARS-CoV-2 antibodies using four 360 immunochromatographic assays

Evaluation of nine commercial SARS-CoV-2 immunoassays

Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and 366 seroprevalence in

Assessment pROC: an open-source package for R and S+ to analyze and compare ROC curves

Informe sobre estrategia de diagnóstico microbiológico del COVID-376 19 (Actualización)

SARS-CoV-2 specific antibody responses in coronavirus disease patients

Different longitudinal 383 patterns of nucleic acid and serology testing results based on disease severity of

COVID-19 patients

Preanalytical issues affecting the 387 diagnosis of COVID-19

False negative tests for SARS-CoV-2 Infection

Challenges and implications

The diagnostic odds ratio: a 393 single indicator of test performance

Antibody responses to SARS

CoV-2 in patients of novel coronavirus disease 2019

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-403 based seroepidemiological study